Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
381 participants
INTERVENTIONAL
2024-03-11
2025-07-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating various interventions for use in the treatment of autonomic dysfunction symptoms, including cardiovascular complications and postural orthostatic tachycardia syndrome (POTS), in PASC participants. The interventions tested will include non-pharmacologic care and pharmacologic therapies with study drugs.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)
NCT06305793
Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2
NCT05350774
Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease
NCT04432298
Plasma Exchange for Autoimmune Autonomic Failure
NCT00359346
A Phase I Safety Study of NVG-291 in Healthy Adults
NCT05308953
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Interventions will be added to the platform protocol as appendices. Each appendix will leverage all elements of the platform protocol, with additional elements described in the individual appendix.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IVIG
In the IVIG study, randomization will be implemented with 1:1:1:1 allocation among the combination of IVIG/placebo and coordinated/ usual non-pharmacologic care. All participants will receive IVIG or placebo for 9 months (36 weeks) with a follow-up period for an additional 3 months (total study duration for 12 months). See NCT06305793 for additional details.
IVIG + Coordinated Care
Participants will receive IVIG for a duration of 9 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with IVIG administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through a care coordinator.
IVIG Placebo + Coordinated Care
Normal saline given intravenously will be the control (placebo) product. Blinding IV bag and tubing covers will be used for both IVIG and Placebo administration.
Participants will receive IVIG placebo for a duration of 9 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with IVIG placebo administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through a care coordinator.
IVIG + Usual Care
Participants will receive IVIG for a duration of 9 months and usual non-pharmacologic care (control) for a duration of 3 months. This will be concurrent with scheduled IVIG administration.
IVIG Placebo + Usual Care
Normal saline given intravenously will be the control (placebo) product. The normal saline will be of similar formulation and appearance to IVIG.
Participants will receive IVIG placebo for a duration of 9 months and usual non-pharmacologic care (control) for a duration of 3 months. This will be concurrent with scheduled IVIG placebo administration.
Ivabradine
In the ivabradine study, randomization will be implemented with 1:1:1:1 allocation among the combinations of ivabradine/placebo and coordinated/usual care. All participants receive either ivabradine or placebo for 3 months (12 weeks) with a follow-up period for an additional 3 months (total study duration of 6 months). See NCT06305806 for additional details.
Ivabradine + Coordinated Care
Participants will receive Ivabradine for a duration of 3 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with ivabradine administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through care coordinator.
Ivabradine Placebo + Coordinated Care
The control (placebo) oral tablets will be similar to the study drug, ivabradine.
The control packaging matches the packaging.
Participants will receive Ivabradine placebo for a duration of 3 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with ivabradine placebo administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, feedback, nutrition counseling, motivation, education, and assisted care through care coordinator.
Ivabradine + Usual Care
Participants will receive Ivabradine for a duration of 3 months and usual non-pharmacologic care (control) for a duration of 3 months, concurrent with ivabradine administration.
Ivabradine Placebo + Usual Care
The control (placebo) oral tablets will be similar to the study drug, ivabradine.
The control packaging matches the packaging.
Participants will receive Ivabradine placebo for a duration of 3 months and usual non-pharmacologic care (control) for a duration of 3 months, concurrent with ivabradine placebo administration.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IVIG + Coordinated Care
Participants will receive IVIG for a duration of 9 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with IVIG administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through a care coordinator.
IVIG Placebo + Coordinated Care
Normal saline given intravenously will be the control (placebo) product. Blinding IV bag and tubing covers will be used for both IVIG and Placebo administration.
Participants will receive IVIG placebo for a duration of 9 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with IVIG placebo administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through a care coordinator.
Ivabradine + Coordinated Care
Participants will receive Ivabradine for a duration of 3 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with ivabradine administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through care coordinator.
Ivabradine Placebo + Coordinated Care
The control (placebo) oral tablets will be similar to the study drug, ivabradine.
The control packaging matches the packaging.
Participants will receive Ivabradine placebo for a duration of 3 months and coordinated non-pharmacologic care for a duration of 3 months, concurrent with ivabradine placebo administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, feedback, nutrition counseling, motivation, education, and assisted care through care coordinator.
IVIG + Usual Care
Participants will receive IVIG for a duration of 9 months and usual non-pharmacologic care (control) for a duration of 3 months. This will be concurrent with scheduled IVIG administration.
IVIG Placebo + Usual Care
Normal saline given intravenously will be the control (placebo) product. The normal saline will be of similar formulation and appearance to IVIG.
Participants will receive IVIG placebo for a duration of 9 months and usual non-pharmacologic care (control) for a duration of 3 months. This will be concurrent with scheduled IVIG placebo administration.
Ivabradine + Usual Care
Participants will receive Ivabradine for a duration of 3 months and usual non-pharmacologic care (control) for a duration of 3 months, concurrent with ivabradine administration.
Ivabradine Placebo + Usual Care
The control (placebo) oral tablets will be similar to the study drug, ivabradine.
The control packaging matches the packaging.
Participants will receive Ivabradine placebo for a duration of 3 months and usual non-pharmacologic care (control) for a duration of 3 months, concurrent with ivabradine placebo administration.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Previous suspected, probable, or confirmed SARS-CoV-2 infection, as defined by the Pan American Health Organization12ɸ ɸ Enrollment of participants with suspected or probable SARS-CoV-2 infection will only be allowed if they occurred before May 1, 2021 and be limited to no more than 10% of the total sample size per Study Drug Appendix. Refer to the Manual of Procedures (MOP) for details.
Suspected case of SARS-CoV-2 infection - Three options, A through C:
A. Meets the clinical OR epidemiological criteria.
1. Clinical criteria: Acute onset of fever AND cough (influenza-like illness) OR Acute onset of ANY THREE OR MORE of the following signs or symptoms: fever, cough, general, weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea, nausea, diarrhea, anorexia.
2. Epidemiological criteria: Contact of a probable or confirmed case or linked to a COVID-19 cluster; or B. Presents with acute respiratory infection with history of fever or measured fever of ≥ 38°C; and cough; with onset within the last 10 days; and who requires hospitalization); or C. Presents with no clinical signs or symptoms, NOR meeting epidemiologic criteria with a positive professional use or self-test SARS-CoV-2 antigen-Rapid Diagnostic Test.
Probable case of SARS-CoV-2 infection, defined as meets clinical criteria above AND is a contact of a probable or confirmed case or is linked to a COVID-19 cluster.
Confirmed case of SARS-CoV-2 infection - Two options, A through B:
A. A person with a positive nucleic acid amplification test, regardless of clinical criteria OR epidemiological criteria; or B. Meeting clinical criteria AND/OR epidemiological criteria (See suspect case A). With a positive professional use or self-test SARS-CoV-2 Antigen-Rapid Diagnostic Test.
3. Moderate, self-identified autonomic symptoms (defined as COMPASS-31 \>25) following a SARS-CoV-2 infection that has persisted for at least 12 weeks and is still present at the time of consent
4. OHQ/OIQ, question 1 score \>2
Exclusion Criteria
2. Known active acute SARS-CoV-2 infection ≤ 4 weeks from enrollment
3. Known renal failure (eGFR \<20ml/1.73 m²)
4. Known atrial fibrillation or significant cardiac arrhythmia
5. Known cardiovascular conditions such as heart failure (Class 3-4), severe valvular disease, symptomatic ischemic coronary artery disease, revascularization for PAD/CAD within the past 6 months
6. Clinically significant atherosclerotic disease, defined as history of stroke or myocardial infarction or revascularization 6 months prior to enrollment and/or current symptomatic angina
7. Existing uncontrolled hypertension
8. History of significant hypercoagulability disorders
9. Active or recent thrombosis
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kanecia Obie Zimmerman
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kanecia Obie Zimmerman
Associate Professor of Pediatrics
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christopher Granger, MD
Role: STUDY_CHAIR
Duke Clinical Research Institute
Cyndya Shibao, MD
Role: STUDY_CHAIR
Vanderbilt University Medical Center
Peter Novak, MD
Role: STUDY_CHAIR
Harvard
Pam Taub, MD
Role: STUDY_CHAIR
University of California, San Diego
Tae Chung, MD
Role: STUDY_CHAIR
Johns Hopkins University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
East Alabama Medical Center - Appendix B Only
Opelika, Alabama, United States
Center for Complex Neurology - Appendix A & B
Phoenix, Arizona, United States
University of Arkansas for Medical Sciences - Appendix A & B
Little Rock, Arkansas, United States
University of California San Diego - Appendix B Only
La Jolla, California, United States
Cedars Sinai Medical Center - Appendix A & B
Los Angeles, California, United States
Stanford University - Appendix B Only
Stanford, California, United States
University of Colorado Anschutz Medical Campus Clinical and Translational Research Center (CTRC) - Appendix A & B
Aurora, Colorado, United States
MedStar National Rehabilitation Hospital - Appendix B only
Washington D.C., District of Columbia, United States
University of Florida Health - Appendix A & B
Gainesville, Florida, United States
Lakeland Regional Medical Center - Appendix A & B
Lakeland, Florida, United States
Innovation Clinical Trials Inc.- Appendix A & B
Palmetto Bay, Florida, United States
Grady Memorial Hospital - Woodruff Memorial Research - Appendix A & B
Atlanta, Georgia, United States
Morehouse School of Medicine - Appendix A & B
Atlanta, Georgia, United States
Queens Medical Center - Appendix B Only
Honolulu, Hawaii, United States
Rush University Medical Center - Appendix B Only
Chicago, Illinois, United States
University of Illinois at Chicago - Appendix A & B
Chicago, Illinois, United States
NorthShore University HealthSystem - Evanston Hospital - Appendix B Only
Evanston, Illinois, United States
University of Iowa - Appendix A & B
Iowa City, Iowa, United States
University of Kansas Medical Center CTSU Fairway - Appendix A & B
Fairway, Kansas, United States
University of Kentucky Medical Center - Appendix A & B
Lexington, Kentucky, United States
University Medical Center New Orleans - Appendix A & B
New Orleans, Louisiana, United States
Johns Hopkins Hospital - Appendix A Only
Baltimore, Maryland, United States
Brigham and Women's Hospital - Appendix A Only
Boston, Massachusetts, United States
Henry Ford Hospital - Appendix A & B
Detroit, Michigan, United States
Mayo Clinic - Appendix A & B
Rochester, Minnesota, United States
University of Mississippi Medical Center - Appendix A & B
Jackson, Mississippi, United States
Washington University School of Medicine - Appendix B Only
St Louis, Missouri, United States
University at Buffalo - Appendix A & B
Buffalo, New York, United States
St. Lawrence Health Medical Campus - Appendix A & B
Canton, New York, United States
Columbia University Irving Medical Center - Appendix A & B
New York, New York, United States
Stony Brook University Hospital - Appendix A & B
Stony Brook, New York, United States
Montefiore Medical Center - Moses Campus - Appendix B
The Bronx, New York, United States
Duke University Hospital - Appendix A & B
Durham, North Carolina, United States
East Carolina University - Appendix B Only
Greenville, North Carolina, United States
Cleveland Clinic - Appendix A & B
Cleveland, Ohio, United States
University of Oklahoma Health Science Center - Oklahoma Clinical and Translational Science Institute - Appendix A & B
Oklahoma City, Oklahoma, United States
Oregon Health and Science University - Appendix A & B
Portland, Oregon, United States
Kent Hospital - Appendix A & B
Pawtucket, Rhode Island, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
National Neuromuscular Research Institute - Appendix A & B
Austin, Texas, United States
Southwest Family Medicine Associates - Appendix A & B
Dallas, Texas, United States
University of Texas Health Science Center at Houston
Houston, Texas, United States
University of Texas Health Science Center at San Antonio - Appendix A & B
San Antonio, Texas, United States
Bateman Horne Center - Appendix B Only
Salt Lake City, Utah, United States
Vermont Lung Center, University of Vermont - Appendix B Only
Burlington, Vermont, United States
University of Virginia Health System, University Hospital - Appendix A & B
Charlottesville, Virginia, United States
Sentara Norfolk General Hospital - Appendix A & B
Norfolk, Virginia, United States
Evergreen Hospital Medical Center - Appendix A & B
Kirkland, Washington, United States
Providence Medical Research Center - Appendix A & B
Spokane, Washington, United States
Marshall Health - University Physicians and Surgeons - Appendix A & B
Huntington, West Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Informed Consent Form
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OTA-21-015G
Identifier Type: OTHER
Identifier Source: secondary_id
Pro00112597
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.